Merck is profoundly disappointed by the decision of the Government of Brazil (GOB) to issue a compulsory license for STOCRIN (efavirenz), which would break Merck & Co., Inc.'s patent and make it possible for efavirenz to be produced by a generic manufacturer. Merck has attempted to negotiate in good faith with the GOB, but a fair offer on STOCRIN has been rejected. ...we believe their action is not in the best interests of patients in Brazil and around the world. Merck continues to share with the GOB the common objective of improving the health and welfare of those living with HIV/AIDS.